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The current study was designed with the purpose to determine the possible influence of lens 
opacification on macular pigment optical density (MPOD) measurements. 
In 86 eyes of 64 patients with planned cataract surgery the MPOD was prospectively measured 
before and after the implantation of a blue-light filtering intraocular lens (AlconSN60WF). For 
MPOD measurements the one-wavelength reflection method by modified fundus camera 
Visucam 500 Carl Zeiss Meditec AG was used. The median of the maximum optical density 
(MaxOD) and the median of the mean optical density (MeanOD) measurements of macular 
pigment across the subject group were evaluated. 
Statistically significant deviations were established between pre-operative and post-operative 
MPOD measurements, the absolute values were generally lower after cataract extraction.  Larger 
changes were observed in elderly patients and in patients with progressed stage of cataract. 
In conclusion, cataract presented a strong effect on MPOD measured by one-wavelength 
reflection method. Particular care should therefore be taken when evaluating MPOD using this 
method in elderly patients with progressed stage of cataract. Future optimization of correcting 
parameters of scattered light and consideration of cataract influence may allow more precise 







II  List of abbreviations 
 
AMD    age-related macular degeneration 
i.e. (id est)   that is 
e.g. (exempli gratia) for example 
et.al. (et alii)  and others 
L    lutein 
MaxOD   maximum of the optical density 
MeanOD   mean of the optical density 
Meso-Z   meso-zeaxanthin 
MP    macular pigment 
MPOD    macular pigment optical density 
n    number of (eyes) 
nm    nanometer 
ODU    optical density units 
RPE   retinal pigment epithelium 
SD    standard deviation 
VEGF   vascular endothelial growth factor 
vs    versus  
Q1    lower quartiles 
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1.1. Age-related macular degeneration 
Age-related macular degeneration (AMD) is known to be the one of the leading causes for 
reading disability and irreversible blindness in the elderly population of the western world [1]. 
At the initial stages, in particular central vision is affected, which is responsible for important 
daily tasks allowing a person to recognize faces, read a book or newspaper and/or drive a car.  
1.1.1 Risk factors 
For development and progression of AMD several risk factors have been introduced. Thus, for 
example, advanced age has been shown to be associated with growing prevalence, incidence and 
progression of this disease [2-7]. Systemic risk factors of AMD development include, among 
others, history of cigarette smoking [8-9], obesity [10] and cardiovascular diseases [9, 11-12]. 
Also several genetic factors influencing biological pathways e.g. complement processes, 
angiogenesis and lipoprotein pathways as well as family history of AMD have been shown to be 
related to AMD [11, 13-27]. Hyperopic refraction was shown to be an ocular risk factor for 
developing of the AMD [28]. Previous cataract surgery, iris color, ethnicity and gender have been 
inconsistently reported to be further risk factors [9, 29-30]. 
 
1.1.2 Classification and pathomechanisms of AMD 
 
Although currently multiple classification schemes and grading systems for AMD have been 
developed [31-39], at present no universally accepted precise staging scale exists. Therefore and 
considering the fact that the classification proposed by the Age-Related Eye Disease Study is now 
increasingly used [40-41], in present report this classification is presented to emphasize the 
growing importance  of AMD and diagnostic of this disorder. According to this classification the 
stages of AMD can be categorized in general as early, intermediate and late. The late, which is 
also named advanced stage, is divided into “dry” and “wet” forms. 
 
In the pathomechanisms of AMD the transport processes of retinal pigment epithelium (RPE) 
have been assumed to play an important role [42]. RPE is a part of the blood-ocular barrier and 
lies posterior to the photoreceptors. The main functions of the RPE are cytokine secretion, 
photoreceptor phagocytosis and nutrient transport of fluids and ions between photoreceptors 





Thus in the early and intermediate stages of AMD the transport of nutrients and wastes slows 
down and this results in increasing accumulation of wastes under the RPE. There they form 
yellow deposits, which are called drusen [44-45]. In order to carry on with pathogenesis of AMD 
the term of drusen should be depicted. Drusen are classic initial lesions of early stages of dry 
AMD and can be categorized as hard and soft drusen on the basis of the appearance of their 
borders. Hard drusen are sharply demarcated small lesions and have discrete margins [46]. 
They are deposits of cholesterol and other materials below the RPE. Soft drusen have indefinite 
borders, they are large and confluent [46] and are commonly assumed to be precursors of 
advanced AMD [47].  Besides, strong correlation was found between the presence of reticular 
pseudodrusen and geographic atrophy in dry AMD. The association between these lesions 
suggests that reticular pseudodrusen are an early manifestation of the process which is leading 
to progression of geographic atrophy in dry AMD [48]. 
The early stage of AMD is characterized by the presence of few small or medium sized drusen or 
retinal pigmentary abnormalities. Additionally, areas with hyperpigmentation and 
hypopigmentation can be presented in RPE. With further slowing down in RPE transport the 
overlying photoreceptors become damaged leading over time to blindness of the eye. To sum up, 
such drusen, hyperpigmentations or small hypopigmentations, without visible choroidal vessels 
can be characterized as early stage of AMD. Patients with early AMD are usually asymptomatic 
and have generally mild visual loss.  
The intermediate stage represents at least one large druse or large number of medium sized 
druses with pigmentation disorders. While during the early stages of AMD visual symptoms do 
not attract attention, in following stages severe loss of vision is usual [49].  
The late, also known as advanced stage of AMD, is divided into non-neovascular (“dry”, atrophic, 
or nonexudative) and neovascular (“wet” or exudative) AMD.  
Advanced non-neovascular (“dry”) AMD shows drusen or “geographic atrophy”, which is 
extending to the center of the macula. Such “geographic atrophy” starts with sharply demarcated 
hypopigmented area with large visible choroidal vessels, which shows progressive atrophy of 
the RPE, photoreceptors and choriocapillaris [50]. Patients get clinical disorders very slowly, 
thus gradual visual loss over the course of months to years is not rare. Such slow progressive 
loss of the vision over many years tends to cause gaps in an image, which are mostly remarked 
by reading the text [42]. The fovea can be spared until late in the disease.  
Advanced neovascular (“wet”) AMD is stage of AMD which shows the proliferation of new 
vessels, either under the RPE or breaking through the RPE named choroidal neovascularization, 
or within the neural retina known as retinal angiomatous proliferation. This proliferation of new 
vessels results in different stage in exudates like fluid, lipids and blood, fibrous scarring and 
detachment of the RPE from the choroid,  which on their part can lead to death of the 





The damage of the RPE and chronic inflammatory response are shown by de Jong to be 
responsible for retinal atrophy and expression of angiogenic cytokines such as vascular 
endothelial growth factor (VEGF) [42, 43]. In recent years the importance of VEGF in the 
pathomechanism of AMD has been developed. VEGF is a key regulator of angiogenesis and can 
lead to determining of vascular growth and neovascular regression [59]. Thus, it is believed to 
be substantial for choroidal neovascularisation and development of retinal angiomatous 
proliferation [60].  
As a result, patients develop rapid visual loss describing in particular worsening of central 
vision. Typically the objects in that portion of the visual field appear distorted or wavy, which is 
clinically known as metamorphopsia [61-62]. Additionally patients complain about dark patch in 
central vision named scotoma. If untreated, progression can be fast, resulting in very poor visual 
acuity. Also sudden visual loss within couple of days to week is typically. The reason for such fast 
vision loss is usually fluid accumulation secondary to choroidal neovascularization or subretinal 
hemorrhage. 
 
1.1.3 Treatment:  
 
Summarizing the above mentioned, it can be emphasized that underlying mechanisms of 
pathogenesis of AMD remain until today incompletely understood [81]. On the other side, it is 
well known that photoreceptor cells cannot regenerate [82] and therefore the promising 
therapy of AMD is possible only for certain stages. 
 
Lifestyle and dietary modifications including inter alia control of blood pressure and body-mass 
index as well as smoking determination are important treatment strategies for all stages of AMD. 
Besides increased dietary intake of antioxidants, beta-carotene vitamine C and E and zink n−3 
long-chain polyunsaturated fatty were shown to decrease the risk of the development of 
neovascular AMD [63-64]. 
 
Supplemetation  
High dietary intake or supplementation of lutein, zeaxanthin and antioxidants results in relevant 
increase in macular pigment, which appears to lower the risk of AMD and improve human visual 
function [66-69]. Furthermore a positive influence of supplementation of lutein and zeaxanthin 
on drusen morphology as well could be shown [65]. 
Also the Lutein Antioxidant Supplementation Trial study showed that an enhancement of the 





of 12 months. Furthermore the greatest changes in MPOD appeared in subjects with lowest 
initial MPOD [70]. 
 
Intravitreal antiangiogenic therapy is the primary treatment for neovascular AMD. During this 
procedure anti-VEGF agents ranibizumab (Lucentis, Novartis), aflibercept (Eylea, Bayer) and 
bevacizumab (Avastin, Roche) are injected directly into the vitreous. In recent years such 
antiangiogenetic agents become increasingly well-established therapies and have almost 
replaced earlier treatment options such as Ocular Photodynamic Therapy or Laser 
Photocoagulation [91]. 
 
Ocular Photodynamic Therapy is characterized by intravenous infusion of photosensitive drug, 
named verteporfin, which accumulates preferentially in neovascular membranes and its 
activation with the use of a 689-nm laser beam focused over the macula, followed by dye 
activation with infrared light. The activation results in the formation of cytotoxic oxygen species 
[71], which in their part damage the cellular structures of endothelium with following platet 
activation, causing localized choroidal neovascular thrombosis within the treated area [72]. In 
neovascular age-related macular degeneration such described photodynamic therapy is 
assumed to limit the visual loss [73]. 
 
 Argon-Laser Photocoagulation Therapy was once the most common therapy for neovascular 
age-related macular degeneration [74]. During the procedure, a laser is used to 
finely cauterize ocular blood vessels. Due to the fact of possible creation of large retinal cicatrice 
through the treatment itself, as well as the lack of vision gain and the high recurrence rates, 
today it is used only incidentally for discrete small extrafoveal choroidal neovascularisation 
lesions, which are localized distant from the fovea [75]. 
 
Vitreoretinal surgery including, for example, surgical extraction of choroidal neovascularization 
was researched before and was shown to have poor efficacy [76]  Studies investigating 
subretinal injection of tissue plasminogen activator combined with intravitreal air injection [77-
79] as well as those researching the effect of surgical relocation of the macula [80] showed 
improved visual outcomes after several months of follow up period. However, due to the 
potential for complications and rate of recurrence of choroidal neovascularisation as well as to 
the deficiency of long-term studies data, vitreoretinal surgery was relegated by others described 
treatment procedures.   
Some benefit for retinal angiomatous proliferation by combinations of treatment processes e.g. 





To sum up, incomplete comprehension of pathomechanisms of AMD and consequently a lack of 
the “gold-standard” therapy of this disorder are main reasons why treatment strategies of AMD 
focus on preventing the progression of the disease process as, for example, by supplementation 
or dietary intake of lutein and zeaxanthin. Furthermore, it has been considered that macular 
pigment (MP) is playing an important role in diagnostic and treatment methods of macular 
diseases. Considering this fact the following chapter concentrates on the constitution and 
characteristics of the MP.   
 
1.2. Macular pigment 
Macular pigment (MP) has become the focus of much research in recent years. It is a yellow 
carotenoid pigment located temporal to the optic disc on the fundus in the posterior pole of the 
retina [83-84]. The foveal region with MP is assumed to have influence on the central vision [85], 
because it contains the densest concentration of photoreceptors within the retina. MP consists of 
lipid-like molecules, which are named retinal carotenoids and include lutein (L), zeaxanthin (Z), 
and meso-zeaxanthin (meso-Z). Carotenoids are part of natural pigments which are synthesized 
de novo by plants and some microorganisms for the photoprotection and coloration [86]. 
Considering this and due to the fact that humans are not able to synthesize carotenoids, MP is 
completely of alimentary origin. L and Z have the ability to cross the blood-retinal barrier to 
accumulate in the central or macular retina [87].  As carotenoids contain oxygen they also are 
named xanthophylls. 
According to previous studies, MP is located in receptor axons and in the inner plexiform layer 
[88]. The highest density of the MP is concentrated in the foveal region of the macula. Here they 
are commonly assumed to act as antioxidants and as optical filters for blue light, the most 
phototoxic region of the visible spectrum [89].  The MP decreases approximately exponentially 
toward the periphery [90]. Meso-Z is found only in the central macula, but neither in the diet nor 
in serum. Consequently it is assumed that the meso-Z is generated at the retina folllowing L 
isomerization [87].  
 
1.3. The role of the macular pigment 
The increased interest in MP in recent years has been justified by its characteristics as well as by 
its commonly assumed protective role in the fovea. The role of MP in various aspects of visual 
performance was evaluated and reported by several studies. Especially the role of color vision, 





Furthermore, the positive association of the MP with the best corrected visual acuity, which was 
reported in numerous studies [92, 94-95], suggests its possible role in optimization of visual 
acuity. The visual acuity for their part relates strongly to a quality of life [99], which emphasizes 
the importance of MP role. 
As mentioned above, a widely shared assumption exists, that MP plays protective and preventive 
role in relation to the pathogenesis of AMD. Its putative protective role is based on a 
combination of its anatomical, chemical and physical properties. The first one is the commonly 
assumed ability to absorb energy-rich blue radiation of wavelengths of 390 until 540nm acting 
like an optical filter.  Second one is working like a powerful antioxidant by scavenging of free 
radicals formed by oxidative stress [100-102]. Thus, Stahl and colleagues showed in their 
research that small concentration of carotenoids of the macular pigment, which are acting like 
natural radical scavenger, might be a further risk factor for increasing efficacy of free radicals 
[103]. 
Summing up macular pigment is a part of the retina, which is responsible for the high spatial 
resolution, sharpest visual acuity, colour vision and protection against macular diseases [92]. 
Since age is the major risk factor for the development of AMD, a following question to answer 
comes up. Is there a possible age-dependence of the MP, measured as macular pigment optical 
density (MPOD)? This question was the subject of research in numerous studies over the years 
[104-120], but no clear conclusion has been reached, primary because of different methods to 
measure MP employed across studies. For example, Berendshot and Van Norren declared after 
comparing values measured with different methodes (two setups for Fundus Reflectance 
Spectroscopy, Scanning Laser Ophthalmoscope for obtaining MP reflectance and Scanning Laser 
Ophthalmoscope for depiction of autofluorescence maps), that there was no significant age-
effect influencing the optical density of the MP [104]. Only Heterochromatic Flicker Photometry 
(HFP) showed a slight decrease of measured MPOD with increasing age [104]. Similarly, Loan et 
al. found a small decrease of MP with increasing age when measuring MPOD by using HFP [105]. 
On the other hand, Ciulla reported that even when elderly subjects with cataracts and AMD are 
enclosed; MP measured with HFP did not change significantly with age when analyzed across 
the group [106]. 
A large number of other previous studies based on Autofluorescence [107], Fundus 
Reflectometry [108], psychophysical methods [109], or High-performance Liquid 
Chromatography [110] examined MPOD changes in relation to age. Although the results varied, 
the majority of the studies, which reported on the age effect on MPOD, presented with an age-
related decline in MPOD [81, 111-118, 122, 121]. Some other studies, on the other hand, which 





methods based on HFP did not detect any age-related difference in MPOD [104, 110, 119-120], 
even when elderly subjects with cataracts were considered [106].  
To sum up, statistically significant change in MPOD was investigated by numerous studies in 
relation to the age, but there exist on the other hand also a lot of studies that have investigated 
no relationship between age and MPOD. The discrepancy in results of the different studies may 
be related to differences in subject selection, methods of measurement or size of the sample. 
Considering the fact, that the age-dependence remains unsettled topic until today, further 
investigation of this possible relation was among other things the subject of the present study.  
 
1.4.  Importance of the measurement of the macular pigment 
Due to the importance of MP and its functions, the question arises, why MP measurements have 
been considered important? The size and distribution of MP, measured as MPOD, are believed to 
correlate with some risk factors for macular diseases in general. Less MP might result in an 
increased risk of developing the disease and vice versa. Thus, the longstanding suggestion, that 
MP makes a significant contribution to protection against the AMD, can be supported by 
following facts:     
- Analysis of retinas of human donors with AMD and eyes in healthy people with high risk for 
AMD (like history of smoking or family predisposition) show lower levels of MPOD [81, 115, 
122].  
- Compared to the healthy subjects reduced MPOD levels were found by the patients with an 
early stage of AMD [123]. 
- Wüstemeyer detected in his study, using a modified Scanning Laser Ophthalmoscope, 
statistically significant higher MPOD values in healthy subjects in comparison with patients with 
dry AMD [124]. 
Considering these facts, MP may give information about the possible risk situation relating to 
macular diseases. 
Furthermore, growing evidence exists that MPOD can be increased by a carotenoid-rich dietary 
modification [125-126] or by the ingestion of supplements like L and Z by healthy subjects and 
patients with beginning stages of AMD [67, 68, 125]. In this way, dietary intake or 
supplementation of lutein and zexanthin could give some degree of protection or could 
potentially slow the progression in subjects with family predisposition or early stage of disease. 
Thus, the longstanding suggestion of the importance of MP monitoring over the time can be 
confirmed by several studies, which identify the long term influence of supplementation on the 





monitoring of supplementation or dietary intake of L and Z by repeated measurements of MP 
over time might be important to track the effects of a particular treatment.  
To sum up, the monitoring measurements of MP are potentially useful to uncover predictors of 
particularly early stage of AMD and to provide information about the disease progression and 
success of supplementation with L and/or Z or any other treatment. 
 
 
1.5. Methodes for measurement of macular pigment 
 
Since the importance of MP measurements became more understandable, various different 
methods to measure the MP were developed. Thus, MPOD can be measured in vitro or in vivo.  
High-performance Liquid Chromatography [129] and Microdensitometry [130] are techniques 
to measure the MPOD in vitro. These techniques are not suitable to common use in everyday 
clinical practice. For this issue there are two categories for in vivo measurement of optical 
density of the MP. The first category includes psychophysical methods that require the active 
response from the subject. Those are Heterochromatic Flicker Photometry and Minimum Motion 
Photometry. These are also the most commonly used methods. 
The second group contains objective methods, which require minimal input from the subject and 
includes Fundus Autofluorescence, Resonance Raman Spectroscopy, Fundus Reflectometry and 
other. At present there is no technique that could be characterized as a true “gold-standard” for 
the measurement of MPOD. Different studies employed different subjective or objective 
measurement techniques, which is one of the main reasons why values for measured MPOD vary 
across research reported. Also the macular carotenoid concentrations, which can be described 
by measuring of MPOD, vary widely among individuals. The following section concentrates on 
the short introduction of advantages and disadvantages of measure methods. 
The Heterochromatic Flicker Photometry is the most commonly used psychophysical method to 
measure MP in clinical research. Heterochromatic Flicker Photometry is noninvasive, low-priced 
and there is no need for pupil dilation [126]. On the other side its main disadvantage is a 
dependence on the patient’s ability to comprehend the task. Therefore examiner and patient 
need to learn the examination skill and procedure before the measurement [131]. Furthermore 
the experimental conditions, e.g. head or eye movement or flicker frequency may affect the 
accuracy and measured values of MPOD [132]. Considering these facts this method is unsuitable 
for some individuals like children or elderly with insufficient visual fields or people with 





Motion photometry are similarly to those of HFP.  No pupil dilation is needed. The main 
disadvantage is that a good comprehension of the task by the subjects is required. 
To carry on with introduction it is important to explain also the characteristics of the objective 
methods.  
 A fast measurement can be obtained with Fundus Autofluorescence. This objective method uses 
the fluorescence of lipofuscin which is located in the RPE cells [133-135]. Lipofuscin has the 
ability to absorb short-wavelength radiation between 400-580nm. Advantage of Fundus 
Autofluorescence is no need of subject participation and for this reason it is applicable to many 
subjects’ populations. Measurements of MP distribution are within a short period of time 
possible. Disadvantages of Fundus Autofluorescence are the need for pupil dilation, expensive 
equipment and unpleasant light levels during the measurement. Furthermore the measurements 
of this method might be influenced by lens opacities [132].  
The main difference of Resonance Raman Spectroscopy in compare to other techniques is that it 
measures absolute levels of MP in a 1mm (3.5°) area, without any peripheral consideration. 
Advantages are rapid measurements that provide detailed spatial distribution of the MP and that 
are possible also in individuals with reduced visual acuity. Disadvantages are needed pupil 
dilation, questionable validity, expensive and highly specialized equipment, attenuation of the 
Raman signal by changes in ocular media. Furthermore, Raman counts are not simply 
convertible to MP optical density units (ODU), therefore the direct comparison with other 
techniques might be complex.  
Fundus Reflectometry is another fast objective method that may be used also for elderly 
handicapped patients. The measurement of reflected light from the retina and choroid makes it 
possible to assess the MP by Fundus Reflectometry [136-138]. The distribution of the MP is 
shown on density maps. Disadvantages of Fundus Reflectometry are the need of pupil dilation 
and unpleasant light flash because of the necessity of photopigment bleaching [132]. 
In 2010 Schweitzer and co-workers introduced a new simple objective method based on one-
wavelength reflection fundus imaging. Despite the fact that one-wavelength reflection method is 
a simplified one, significant correlation was found in comparison with two –wavelength-
autofluorescence method for determination of the optical density of MP [139]. Considering this 
fact, the measurements in the current study were carried out based on using this objective 
method.  
The principe of this method is based on one-wavelength reflection photometry, which employs 
the local and spectral selectivity of xanthophyll. The local selectivity indicates that xanthophyll is 





absorb blue light for wavelength shorter than 540nm. During the measurement the fundus is 
illuminated with blue light. Under illumination with the wavelength at 480 nm, which is near the 
absorption maximum of xanthophyll, the fundus can be determined as a uniform reflecting 
surface, where the increased absorption in the region of fovea can be considered.  The 
logarithmic ratio of the virtual fundus reflection below the macular pigment compared to the 
macular reflection leads to the optical density of the MP. Hereby the fundus reflection and 
illumination inhomogeneity are accounted for by a shading function. The logarithmic ratio of 
every pixel results in spatial distribution of the optical density of MP. Area, in which the optical 
density exceeded a defined threshold, volume as a sum of the density of all pixels, maximal 
optical density and mean optical density over all pixels are four parameters, which describe the 
spatial distribution of MP. 
 
1.6. Possible factors with influence on the measurement results 
Macular pigment measurement is generally affected by the density of the media as the light must 
go through tissue. Such eye media include e.g. cornea, aqueous humor, lens and vitreous. As 
previously established, these optical media scatter the light to a certain degree due to their 
biological configuration [140]. The scattering and absorption of the light due to this described 
effect increase with rising patient age. It has long been recognized, that it is in particular the 
crystalline lens that tends to influence the transmittance most strongly [141-142]. The stray 
light of crystalline lens is also known to increase with the patient age [143]. A lot of studies 
reported the exponential change in the amount of scatter with age. There is an increase of 
insoluble and soluble material with age in the human lens, which is believed to be responsible 
for this age-dependent increase in scatter [144]. 
Moreover, in-vitro performed examinations of the lenses from donor eyes showed an increased 
scattering with increased degree of cataract [145]. Thus, the lens appears to be an important 
source of stray light and measurements of MPOD could be affected by, for instance the light loss 
due to reflection and scattering by the dense lens [146-147]. The human crystalline lens owns 
the property to yellow with increasing age. Because of this fact the older lens transmits less blue 
light than a younger one [148]. It might provide a part of the physiological protection against 
AMD at this stage of life [149]. In other words, the cataract absorbs the blue light, which may 
affect the accuracy of MPOD measurement. In this way measurements of MPOD in cataract 
patients might be influenced by lens opacities. So, when taking measurements of MPOD by the 





Previous investigations for MPOD measurements using Autofluorescence Spectrometry showed 
reduced signals in a 488-nm autofluorescence image by cataract presence [142, 150-153].  
Also the analysis of MP by Raman-scattering method [122, 121, 154] seems to be dependent on 
accurate data of the transmission of ocular media, in particular by testing the elderly patients. 
On the other hand it is assumed that psychophysical techniques remain unaffected by individual 
differences in opacity of the crystalline lens and could be used to measure the MPOD also in 
elderly subjects, even in those with presence of cataract [155].   However, the results of different 
published reports are inconsistent. Therefore, present study aimed to compare MPOD measured 
by one-wavelength reflection method before and after implantation of blue-light filtering 
intraocular lens in cataract patients. A possible future correction of individual differences in pre-
retinal light loss may be important to render MPOD more precisely.  
 
1.7. Cataract and its role as a possible influence factor on measurement results of MPOD 
Enormous importance for medicine and economy of cataract today is justified not only by the 
fact that lens opacity is a most common cause of vision decrease and blindness worldwide but 
also by the frequency of its surgical procedure.  
To carry on with most important possible disrupting factor for the MP measurement, the 
pathomechanisms of cataract should be enlightened. The lens is cellular organ and its 
transparency is due to its protein formation and complex architecture. The pathogenesis of 
cataracts in humans crystallized to be a multifactorial process. Large number of different factors 
e.g. general diseases (diabetes, uraemia, metabolic disorders), nutritional deficiencies or 
disturbances, eye diseases (glaucoma, uveitis, intraocular infections), UV-irradiation, as well as a  
life style (smoking, alcohol consumption) and drug side effects especially from drugs taking as 
long-term therapy(e.g. corticosteroids, phenothiacines, diuretics) are supposed to be 
responsible for the formation of cataracts [156].  It is commonly assumed that the changes in 
proteins or macromolecules inside the crystalline lens are responsible for the changes in the 
opacity of the lenses as well as in their physical properties [157]. One of the numerous molecular 
processes, leading to age-related cataract, is a protein unfolding, that results in protein 
aggregation and changed interaction, the second one is association between native crystallins 
[158]. 
The interaction of denatured proteins with fiber cell membranes increases with the age, 
particularly in the fifth decade of life. This process can influence the proper functioning of 
membrane pores with decreased diffusion of small molecules within the lens. Furthermore, the 





crystalline aggregates to the fiber cell membranes, appear to contribute to the development of 
cataract [159]. The Beaver Dam Eye Study showed that especially nuclear, cortical and posterior 
subcapsular cataract increase with the age. The total incidence of these three forms of age-
related cataract account about 45% for people between the age 55-64 and about 75% for people 
between age 65 and 74 and about 88%for people older than 75 years of age [160]. The recent 
outcomes showed an increase in incidence of cataract surgery in persons older than 65 years 
over the past 20 years [161]. Simultaneously with growing incidence of cataract, increase the 
number of carried out cataract surgeries. Furthermore cataract surgery is a most frequently 
performed surgical procedure in medicine today not least due to the fact of its rapidness in the 
performance but also by the fact that it is the one and only treatment possibility. The clinical 
importance of cataract surgery is emphasized amongst others particularly by the strong relation 
between vision-related quality of life, cognitive impairment and mental status of patients. 
Cataract extraction significantly improves vision-related quality of life in elderly patients. The 
cognitive impairment and (depressive) mental status had been shown to improve in parallel 
[162]. 
To sum up, ageing of the lenses accompanies the balance between processes of molecular 
damage, cytoprotection and consumption of non-renewable resource [163]. Due to the facts of 
rising life expectancy and ageing of the population, the incidence of cataract and cataract 
surgeries is growing and is expected to increases in the near future. These are essential reasons, 
which justify closer inspection of cataract influence on the MP measurements taken over longer 
period of time. 
 
1.8. Main objective of the present study 
To sum up, the effect of possible light absorption, reflection and scattering by the dens lens and 
therefore the influence of cataract on the measured MPOD values have not been adequately 
determined. Thus, the main research questions of current study were concerned with the 
investigation of the influence of different grade of lens opacity and patient age on MPOD 
measurements, carried out using one-wavelength reflection method . Furthermore also the 
possible effect of cataract surgery on values of MPOD was evaluated. Thereby MPOD of the same 
subjects were measured before and after the implantation of blue-light filtering intraocular lens. 
A future correction of individual differences in preretinal light loss can be important to render 













































































3. Additional data to section Results 
The MPOD difference between pre- and post-operative MaxOD and MeanOD measurements for 
all patient eyes is summarized in Figure 6. Here post-operative decrease of optical density in 
both MaxOD and MeanOD is represented (a decrease from pre-operative to post-operative data 
is depicted by a negative relative change). MaxOD decreased by median (Q1/Q3) of 33.8% (-
46.2% /-19.1%) and MeanOD by 44.0% (-54.6%/ -26.6%).  
 
Figure 6: Representation of the relative difference of MaxOD and MeanOD in % 
between pre-operative and post-operative values in general for all patients’ 
eyes. A decrease from pre-operative to post-operative data is depicted by a 
negative relative change. 
The relative difference of the MPOD showed higher rates with increasing patient age (with a 
tendency to smaller MPOD values after cataract removal). In order to investigate this 
relationship in more detail, patients were subdivided into groups by age (Figure 7). Two groups 
were formed, patients who were younger than 70 years of age and those who were 70 years of 
age or older. Figure 5 illustrates clearly that elderly patients presented with larger differences 
between pre-operative and post-operative tests: patients <70 years: (n=25 eyes): median 
change of MaxOD -13.4% (-20.5% / 3.6%), MeanOD -23.6% (-30.5% / -15.3%) versus patients > 
70 years: (n=61eyes): median change of MaxOD -40.5%(-53.2% / -30.1%), MeanOD -47.2%(-






Figure 7: Boxplots of the relative difference from pre-operative to post-operative data 
of MaxOD and MeanOD in % divided into groups by patients age 
(<70years/≥70years). A decrease from pre-operative to post-operative data 
is depicted by a negative relative change. 
 
To determine the effect of different cataract density on MPOD measurements, the grade of lens 
opacity was classified according to the pre-operative MPOD fundus image quality criteria 
represented in Table 2. This specification enabled classification of opacification severity. On the 
basis of this classification all examined eyes were divided into five groups and their relative 
difference of MPOD in each group were demonstrated in Figure 8 and 9.  
Figure 8 highlights the percentage change of MaxOD in relation to the quality of the pre-
operative images. On the basis of this diagram it can be concluded that the group with the 
smallest lens opacity (see Boxplot 1 in Figure 8) offers the smallest changes between pre-
operative and post-operative data. The relative difference of MaxOD in percent increases with 
declining quality of the pre-operative images, which is linked with increasing lens opacity. A 
decrease from pre-operative to post-operative data is depicted by a negative relative change for 
MaxOD investigated. The following median differences of MaxOD were determined for patients 
grouped by the grading scale described in Table 2: grade 1: (n=9 eyes) -27.4% (-42.1%/-19.6%), 
grade 2: (n=26 eyes) -35.0% (-44.2% /-25.3%), grade 3:(n=21 eyes) -34.4% (-45.4%/-11.4%), 






Figure 8: Boxplots of the relative change of MaxOD in % classified according to 
cataract density. Data is presented for each lens opacity group (1-5), see 
Table 2. A decrease from pre-operative to post-operative data is depicted by 
a negative relative change. 
 
Similar to the representation of MaxOD, an increasing opacity of the lens as classified by the 
scheme represented in Table 2 resulted in a larger relative change of MeanOD. The following 
median differences of MeanOD were determined for patients grouped by the grading scale 
described in Table 2: grade 1:(n=9 eyes)  -42.6% (-46.0%/-26.0%),  grade 2: (n= 26 eyes) -
44.1% (-51.8%/26.2%), grade 3: (n=21 eyes) -45.7%(-54.7%/-24.7%), grade 4: (n=25 eyes) -
39.5%(-59.4%/-26.1%), grade 5: (n=5 eyes) -57.0%(-66.1%/-51.4%). In summary, an increase 
in lens density, classified as described above, resulted in a greater relative change of MPOD 






Figure 9: Boxplots of the relative change of MeanOD in % classified according to 
cataract density. Data is presented for each lens opacity group (1-5), see 
Table 2. A decrease from pre-operative to post-operative data is depicted by 


















to obtain the academic degree 
Dr.med. 
 
Macular pigment optical density measurements by one-wavelength reflection 
photometry – Influence of cataract surgery on the measurement results 
submitted by:    Bogdana Komar 
made in:    Medical Faculty of Leipzig University 
     University Hospital Leipzig, 
Department of Ophthalmology 
 
supervisor:     Prof. Dr.med. Jens Dawczynski  
     Dr. Franziska G. Rauscher 
     Dr. med. Renate Wiedemann 
 
Submitted on:    2015 
 
Introduction 
Macular pigment (MP) has become the focus of much research in recent years. The interest is 
focused on the protective role of MP as well as on the ability to measure the macular pigment 
optical density (MPOD) with different methods in vivo. 
MP consists of retinal carotenoids including lutein, zeaxanthin and meso-zeaxanthin. These 
carotenoids are part of natural pigments synthesized de novo by plants and microorganisms 
[86].  Humans are not able to synthesize carotenoids and therefore are reliant on their 
alimentation. 
The role of MP in visual acuity, contrast and glare sensitivity, photostress recovery and color 
vision was evaluated and reported by several studies [92-98]. Moreover MP is commonly 





of the visible spectrum of the light [89, 164-165]. Not only its protective role in the fovea, but also 
its important role in diagnostic and treatment methods of macular diseases has made MP a point 
of interest in recent years [81,166-167]. The possibility to measure and consequently compare 
MP in patients carried out at various points of time emphasized the importance of MP 
acquisition. Thus, the size and distribution of MP, measured as MPOD, are believed to correlate 
with some risk factors for macular diseases in general. Less MP might result in an increased risk 
of developing the disease and vice versa. Thus reduced MPOD levels were shown by patients 
with early stage of age-related macular degeneration (AMD) or a family predisposition for this 
disease in comparison with healthy subjects [81,122,168]. Furthermore growing evidence exists 
that MPOD can be increased by a carotenoid-rich dietary modification [125-126] or by the 
ingestion of supplements like lutein and zeaxanthin in healthy subjects or patients with 
beginning stages of AMD [67-68].  An enhancement of the protective MP layer was shown to 
result in improvement in vision acuity in elderly patients for a period of supplementation [70]. 
In this way, dietary intake or supplementation of retinal carotenoids could give some degree of 
protection or could potentially slow the progression in subjects with early stage of disease. The 
supplementation or dietary intake of lutein and zeaxanthin in their turn can be monitored by 
repeated measurements of MP over time to track the effects of a particular treatment during the 
course of the disease [66-69, 127-128]. 
To sum up, the longitudinal measurements of MP are potentially useful to uncover predictors of 
particularly early stages of AMD and to provide information about the disease progression and 
success of supplementation with lutein and/or zeaxanthin or any another treatment. 
Methods 
Since the importance of MP measurements became clear, various principles to measure the MP 
were explored. MPOD can be measured in vitro or in vivo. In vitro techniques are not suitable to 
common use in everyday clinical practice. For this issue there are two categories for in vivo 
measurement of optical density of the MP: subjective and objective methods. The first category 
includes psychophysical methods which require the active response from the patient. The 
second group contains objective methods which require only minimal input from the patient. At 
present there is no technique that could be characterized as a true “gold-standard” for the 
measurement of MPOD. Different studies employed different subjective or objective 
measurement techniques, which is one of the main reasons why values for measured MPOD vary 
across research reported. 
Considering the advantages of objective principles (e.g. ease, speed and the ability to yield a 
spatial profile of the MP ), the measurements in the current study were carried out using fast, 
objective principle, which was introduced in 2010 by Schweitzer and co-workers [139]. This is a 





MPOD by Visucam 500, Carl Zeiss Meditec AG. The use of this technique for measuring MPOD 
avoids the disadvantages of other objective methods e.g. unequal fundus illumination at the two 
wavelengths used, unequal relation of fluorescence at two excitation wavelength, sophisticated 
procedures. At the same time it provides significant correlation in comparison with two-
wavelength-autofluorescence method for determination of the MPOD [139].  
The principle of one-wavelength reflection method is based on using one-wavelength reflection 
photometry employing the local and spectral selectivity of xanthophyll. During the measurement 
the fundus is illuminated with blue light. Under illumination with the wavelength at 480 nm, 
which is near the absorption maximum of retinal carotenoids, the fundus can be determined as a 
uniform reflecting surface, where the increased absorption in the region of fovea can be 
considered.  The logarithmic ratio of the virtual fundus reflection below the macular pigment 
compared to the macular reflection leads to the MPOD. Area, in which the optical density 
exceeded a defined threshold, volume as a sum of density of all pixels, maximal optical density 
and mean optical density over all pixels are four parameters, which describe the spatial 
distribution of MP. The main focus of attention in current report is set on the maximal optical 
density (MaxOD) and the mean optical density (MeanOD) across all pixels, both measured in 
optical density units (ODU). 
MP measurement is generally affected by the density of the media as the light must go through 
tissue, which scatters the light to a certain degree due to their biological configuration [140]. It 
has long been recognized, that it is in particular the crystalline lens that tends to influence the 
transmittance most strongly [141-142]. It is generally known that with age the lens increases in 
thickness; it becomes more opaque, which can lead to cataract. Stray light of the crystalline lens 
additionally increases with patient age [143]. These influences can affect MP measurement by 
one-wavelength reflection method. For this reason an automatic age-dependent correction 
factor for the grayness level of the lens is introduced by the software of the instrument. The 
post-operative measurements were not affected by these artefacts due to the newly implanted 
clear lens. Therefore the post-operative measurements were carried out by setting the 
”intraocular lens mode” without correction for the opacification of  the lens.  
Main objective of present study 
To sum up, the main research questions of the study were concerned with the investigation of 
the influence of different grades of lens opacity and patient age on MPOD measurements as well 
as the evaluation of the possible effect of cataract surgery on values of MPOD by measuring MPOD of 
the same subjects before and after cataract surgery. 
The study was approved by clinical ethics committee of University Hospital Leipzig and adhered 





of mouth at the University Hospital Leipzig, department of Ophthalmology from July 2011 to 
April 2012. 
Patient characteristics 
All subjects were recruited from a cohort of patients who had cataract that was sufficiently 
symptomatic to warrant extraction. The subjects were invited to participate in the study while 
they were attending a consultation in the eye clinic. Prior to examination, written consent was 
obtained from each patient after careful explanation of the nature and consequences of the 
study, voluntariness as well as demonstration of the test procedure.  All patients underwent 
dilated fundus examination once before and second time 6-8 weeks after completion of the 
cataract surgery. During fundus examination by using a fundus camera Visucam 500 (Carl Zeiss 
Meditec AG) fundus images were made. By means of these images macular pigment optical 
density was measured using an objective one-wavelength-reflection method. A sequence of 
three single measurements was taken and for the examinations of MPOD an average of those 
was calculated for four parameters characterizing MP with a main focus of attention on the 
MaxOD and MeanOD. 
 In total 86 eyes of 64 patients, who had clinical indication for cataract surgery, were included in 
current analysis.  Age ranged from 51.9 to 89.5 years with the mean age (± SD) of 73.4 (+/- 8.3) 
years. The male to female ratio was 28: 36. All cataract extractions were performed by the same 
physician in the Department of Ophthalmology, University of Leipzig, on an outpatient basis. All 
patients underwent planned standard phacoemulsification and implantation of a blue-light-
filtering intraocular lens (Alcon SN60WF). Descriptive and statistical analyses were 
subsequently performed using Minitab statistical software (version 14). 
Results and discussion 
The individual variability of optical density values between subjects was seen in our results as 
well as reported in comparable studies measuring MPOD using variable methods. Considering 
this fact, in following analysis the changes between MPOD values measured before and after 
cataract surgery were expressed as relative percentage.  
Significant differences in MPOD were found between preoperative and postoperative 
measurements analyzed. The results indicated a general tendency for lower MPOD 
measurement levels after cataract surgery. Thus, the data of the present study suggests that 
cataract strongly affected the measurement of MPOD by one-wavelength reflectance method. To 
examine other important factors which could affect the MPOD measurements, further 
classification resulted in subdivision of tested eyes into groups according to patient age and lens 





To estimate the behavior of relative difference of MPOD by patients with various age, tested eyes 
were subdivided into groups according to patient age. Two groups were formed, patients who 
were younger than 70 years of age and those who were 70 years of age or older. The results of 
this analysis represented larger differences between pre-operative and post-operative tests in 
elderly patients.  
Individual absolute values for MPOD measured before cataract extraction showed significant 
correlation with age of the patients. A clear tendency for higher pre-operative MPOD values with 
increasing patient age was represented. On the other side, MPOD measurement of the same 
patients after cataract extraction provided results without any dependency on age. Considering 
the fact that postoperative values may in fact be closer to the true MPOD level of the respective 
patient eye, because of the absence of the main disruptive factor, the dense lens, it should be 
assumed that there is no real correlation between MPOD and patient age. Increasing MPOD 
values with age obtained during pre-operative measurement procedure are therefore thought to 
be affected by the correction term incorporated in the compensation mode. This built-in 
correction factor accounts for increasing grayness levels with increasing age. (Post-operative 
measurements were performed by employing the so called “intraocular lens mode”, i.e. without 
correction). 
Due to the fact that the lens opacity is known to influence the light transmittance and to grow 
with the cataract severity the influence of this factor became a point of interest in following 
analyzing. All preoperative images of tested eyes were divided into five groups according to 
their lens opacification grade. Classification was carried out from slight (lens opacification grade 
1) to strong opacity (lens opacification grade 5) by one person accordingly to the classification 
criteria scheme. Resulting data represented a greater relative change of MPOD values between 
pre-operative and post-operative measurements with an increase in lens density. Further 
classification based on patient age and pre-operative cataract opacity indicated larger 
differences in measured data for the elderly patients with progressed stage of cataract.  
Conclusion 
In conclusion, patient age and intensity of lens opacification were found to impact relative 
differences between pre-operative and post-operative measurements of maximum and mean 
optical density. Particularly elderly patients with progressed stage of cataract showed significant 
changes in MPOD values. MPOD is postulated to be a marker for protection of AMD [81,102,122 
168--169] and its monitoring is potentially useful to provide information about the disease 
progression and success of supplementation [65-66, 67-68- 69, 127-128]. In this way such 
strong deviations as seen in current study might influence possible interpretation of MPOD over 





using one-wavelength reflectance method without further correction factors, may not provide 
accurate data about AMD disease progression or treatment success in cataract patients. Possible 
reason for such significant discrepancy between determined values is thought to be largely due 
to an assessment problem. 
Future optimization of correction parameters for lens opacification, ideally as an individual 
corrective measurement, could contribute to the reduction of measured variation errors and add 
to the understanding of the influence of cataract on the measured values. In such way more 
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Figure 1: Scatter plots of pre-operative macular pigment optical density data as a function 
of age. Depicted are individual results of 86 eyes for MaxOD and MeanOD plotted 
versus age of the patient. Pre-operative measurements were obtained with a 
built-in correction factor of an age-dependent grey-level increase of a typical eye, 
which aims to account for the effect of cataract on the measurements obtained. 
Figure 2: Scatter plots of post-operative macular pigment optical density data as a function 
of age. Depicted are individual results of 86 eyes for MaxOD and MeanOD plotted 
versus age of the patient. Post-operative measurements were obtained in 
intraocular lens mode, which accounted for the implantation of a clear lens. 
Figure 3: Scatter plot of the relative difference of MaxOD and MeanOD, expressed in 
percentage, as a function of age. A decrease from pre-operative to post-operative 
data is depicted by a negative relative change. 
Figure 4: Boxplots of relative difference of MaxOD in % in relation to patient age and 
cataract opacity. Data is presented for each lens opacity group (1-5), see Table 2. 
A decrease from pre-operative to post-operative data is depicted by a negative 
relative change. 
Figure 5: Boxplots of relative difference of MeanOD in % in relation to patient age and 
cataract opacity. Data is presented for each lens opacity group (1-5), see Table 2. 
A decrease from pre-operative to post-operative data is depicted by a negative 
relative change. 
Figure 6: Representation of the relative difference of MaxOD and MeanOD in % between 
pre-operative and post-operative values in general for all patients’ eyes. A 
decrease from pre-operative to post-operative data is depicted by a negative 
relative change. 
Figure 7: Boxplots of the relative difference from pre-operative to post-operative data of 
MaxOD and MeanOD in % divided into groups by patients age 
(<70years/≥70years). A decrease from pre-operative to post-operative data is 
depicted by a negative relative change. 
 
Figure 8: Boxplots of the relative change of MaxOD in % classified according to cataract 





decrease from pre-operative to post-operative data is depicted by a negative 
relative change. 
Figure 9: Boxplots of the relative change of MeanOD in % classified according to cataract 
density. Data is presented for each lens opacity group (1-5), see Table 2. A 
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Table 1: Representation of comparison of macular pigment optical density measurements 
before and after cataract extraction. Measurements of macular pigment optical 
density were carried out before and after cataract extraction. The main focus of 
the analysis considered two parameters: the maximum optical density (MaxOD) 
and the mean of the optical density values (MeanOD). Results are represented as 
a median of the relative differences between each individual’s pre- and post-
operative measurements (Relative difference of MaxOD and Relative difference of 
MeanOD in %).  The median differences of macular pigment optical density are 
shown overall as a group (in general for all included eyes) and subdivided for 
different patient selections (grouped by patient age, grouped by lens 
opacification grade, grouped by patient age and lens opacification grade). 
Negative values of relative differences represent the result of smaller post-
operative MPOD values in comparison to the respective pre-operative dataset. 
The influence of age on the relative change in MPOD was investigated in two 
groups according to each patient’s age (</≥70years). Lens opacification grade is 
indicated numerically (1-5) according to the quality of pre-operative images. 
Number of eyes (n) represents the number of tested eyes. Patient age is 
expressed in years as mean (+/- standard deviation). 
 
Table 2: Grading scale of cataract density according to the quality of pre-operative one-
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